Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.

被引：0

作者：

Rosenberg, Jonathan E.

Gajate, Pablo

Morales-Barrera, Rafael

Lee, Jae-Lyun

Necchi, Andrea

Penel, Nicolas

Zagonel, Vittorina

Sierecki, Mitchell Robert

Piciu, Ana-Maria

Ellinghaus, Peter

Sweis, Randy F.

机构：

[1] Mem Sloan Kettering Canc, New York, NY USA

[2] Ramon y Cajal Univ Hosp, Med Oncol Dept, Madrid, Spain

[3] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[4] Asan Med Ctr, Seoul, South Korea

[5] Univ Ulsan, Coll Med, Seoul, South Korea

[6] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[7] Ctr Oscar Lambret, Dept Med Oncol, Lille, France

[8] Ist Oncol Veneto IRCCS Padova, Oncol Med 1, Padua, Italy

[9] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

[10] Chrestos Concept GmbH & Co KG, Essen, Germany

[11] Bayer AG, Berlin, Germany

[12] Univ Chicago, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5014

引用

页数：2

共 50 条

[1] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
Rosenberg, Jonathan E.
Gajate, Pablo
Morales-Barrera, Rafael
Lee, Jae-Lyun
Necchi, Andrea
Penel, Nicolas
Zagonel, Vittorina
Sierecki, Mitchell Robert
Bao, Weichao
Zhou, Yinghui
Ellinghaus, Peter
Sweis, Randy F.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
Rosenberg, J.
Necchi, A.
Sweis, R. F.
Nakajima, K.
Lu, C.
Nogai, H.
ANNALS OF ONCOLOGY, 2018, 29 : 329 - 329
[3] Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial
Sweis, Randy F.
Gajate, Pablo
Morales-Barrera, Rafael
Lee, Jae-Lyun
Necchi, Andrea
de Braud, Filippo
Penel, Nicolas
Gruenwald, Viktor
Maruzzo, Marco
Meran, Johannes
Ishida, Tatiane Cristine
Bao, Weichao
Zhou, Yinghui
Ellinghaus, Peter
Rosenberg, Jonathan E.
JAMA ONCOLOGY, 2024, 10 (11) : 1565 - 1570
[4] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, Arjun V.
Galsky, Matthew D.
Rosenberg, Jonathan E.
Powles, Thomas
Petrylak, Daniel P.
Bellmunt, Joaquim
Loriot, Yohann
Necchi, Andrea
Hoffman-Censits, Jean
Perez-Gracia, Jose Luis
Dawson, Nancy A.
van der Heijden, Michiel S.
Dreicer, Robert
Srinivas, Sandy
Retz, Margitta M.
Joseph, Richard W.
Drakaki, Alexandra
Vaishampayan, Ulka N.
Sridhar, Srikala S.
Quinn, David I.
Duran, Ignacio
Shaffer, David R.
Eigl, Bernhard J.
Grivas, Petros D.
Yu, Evan Y.
Li, Shi
Kadel, Edward E., III
Boyd, Zachary
Bourgon, Richard
Hegde, Priti S.
Mariathasan, Sanjeev
Thastrom, AnnChristine
Abidoye, Oyewale O.
Fine, Gregg D.
Bajorin, Dean F.
LANCET, 2017, 389 (10064): : 67 - 76
[5] BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)
Rosenberg, J. E.
Bajorin, D. F.
Smith, A.
D'Cruz, C.
Lanasa, M.
ANNALS OF ONCOLOGY, 2018, 29
[6] Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210
Balar, Arjun Vasant
Dreicer, Robert
Loriot, Yohann
Perez-Gracia, Jose Luis
Hoffman-Censits, Jean H.
Petrylak, Daniel Peter
Van Der Heijden, Michiel Simon
Ding, Beiying
Shen, Xiaodong
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Vuky, Jacqueline
Balar, Arjun V.
Castellano, Daniel
O'Donnell, Peter H.
Grivas, Petros
Bellmunt, Joaquim
Powles, Thomas
Bajorin, Dean
Hahn, Noah M.
Savage, Mary J.
Fang, Xiao
Godwin, James Luke
Frenkl, Tara L.
Moreno, Blanca Homet
de Wit, Ronald
Plimack, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2658 - +
[8] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (vol 389, pg 67, 2017)
Balar, A., V
Galsky, M. D.
Rosenberg, J. E.
LANCET, 2017, 390 (10097): : 848 - 848
[9] Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
Vuky, Jacqueline
Balar, Arjun Vasant
Castellano, Daniel E.
O'Donnell, Peter H.
Grivas, Petros
Bellmunt, Joaquim
Powles, Thomas
Bajorin, Dean F.
Hahn, Noah M.
De Wit, Ronald
Savage, Mary
Pang, Lei
Frenkl, Tara L.
Keefe, Stephen Michael
Plimack, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Balar, Arjun V.
Castellano, Daniel
O'Donnell, Peter H.
Grivas, Petros
Vuky, Jacqueline
Powles, Thomas
Plimack, Elizabeth R.
Hahn, Noah M.
de Wit, Ronald
Pang, Lei
Savage, Mary J.
Perini, Rodolfo F.
Keefe, Stephen M.
Bajorin, Dean
Bellmunt, Joaquim
LANCET ONCOLOGY, 2017, 18 (11): : 1483 - 1492

← 1 2 3 4 5 →